Medicine
Etcamah 75 mg tablet
Etcamah 75 mg tablet is a prescription medicine containing Camizestrant for oral use, marketed by AstraZeneca Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store ETCAMAH at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to…
Key facts
- Active ingredient (INN)
- Camizestrant
- Brand
- Etcamah
- Strength
- 75 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 28 tablets
- Marketing authorisation holder
- AstraZeneca Pharmaceuticals
- Manufacturer
- AstraZeneca Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store ETCAMAH at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store and dispense ETCAMAH tablets in the original bottle with desiccant to protect from moisture. Alternatively, dispense ETCAMAH tablets in a USP equivalent tight container and discard after 30 days if stored without desiccant.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L02BA05 Camizestrant
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 September 2026
- Identifiers
- RxCUI 2752687, 2752693DailyMed set ID c54223d3-f3c7-4186-afa0-429d84805826NDC 0310-0075Application NDA220359
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 28 tablet, film coated in 1 bottle, plastic | 0310-0075-01 | AstraZeneca Pharmaceuticals | 4 September 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Camizestrant is a prescription medicine indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Camizestrant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CamizestrantFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ETCAMAH prescribing information (AstraZeneca Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Etcamah: European public assessment report (EPAR) · European Medicines Agency
Need Etcamah 75 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.